# Major Depressive Disorder With Mixed Features - Extension

> **NCT01423253** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Lurasidone

## Key facts

- **NCT ID:** NCT01423253
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423253, "Major Depressive Disorder With Mixed Features - Extension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01423253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*